Robert W. Baird analyst Jack Allen has maintained their neutral stance on CRSP stock, giving a Hold rating yesterday. Jack Allen has given his ...

Shares of CRISPR Therapeutics AG (CRSP) have gained 11.4% over the past four weeks to close the last trading session at $50.36, but there could still be a solid upside left in the stock if short-term ...

We recently published a list of 10 Most Promising Gene Editing Stocks to Buy According to Hedge Funds. In this article, we ...

CRISPR Therapeutics reports mixed third-quarter results. The commercial launch of the first CRISPR-based gene therapy, Casgevy, is progressing well.

CRISPR Therapeutics AG (NASDAQ:CRSP) Just Released Its Third-Quarter Results And Analysts Are Updating Their Estimates ...

In a report released yesterday, Luca Issi from RBC Capital maintained a Hold rating on Crispr Therapeutics AG (CRSP – Research Report), ...

Check the time stamp on this data. Updated AI-Generated Signals for Crispr Therapeutics Ag (CRSP) available here: CRSP.

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...